Enjoy complimentary customisation on priority with our Enterprise License!
According to the insulin delivery systems market analysis, the global insulin delivery systems market is estimated to witness significant growth and will post a CAGR of more than 5% over the forecast period. The paradigm shift of patients from hospitals to specialty clinics is one of the key factors aiding in the insulin delivery systems market growth. In the past, the treatment for diabetes was popular in hospitals where an endocrinologist or a dietician would guide patients in type-1 diabetes management. However, due to the limited visiting slots and high consultation fees, the patients look for alternatives. Recently, some clinics have started to focus only on type-1 and type-2 diabetes management due to which the concept of exclusive specialty clinics centers evolved. As a result, the waiting time of patients has significantly reduced and the availability of medication and delivery systems at the attached pharmacy stores has increased. Also, these centers provide additional benefits like health insurance cards, which allow patients to avail discounts on bills and obtain insulin delivery devices at a relatively lower price. Most of the countries like the US, Canada, India, and Japan have specialty clinics for diabetes management.
According to this market study, the Americas is expected to lead the market with a total market share of over 80% by 2020. North America held the largest market share and is expected to maintain its dominant position during the forecast period. According to the Pan American Health Organization (PAHO) in 2015, health expenditures for diabetes in the Americas will increase by approximately USD 445 billion over the years as the cost of health care for people affected by diabetes is high. This will lead to the use of insulin delivery devices at higher rates among type-1 diabetes population. Several companies are venturing into this market due to which devices like insulin jet injectors and insulin pumps have better penetration into Mexican and Brazilian markets. Moreover, the support from the government has increased over the years, thus, ensuring deeper penetration of insulin delivery devices.
The level of competition in the global insulin delivery systems market is intense as vendors are offering different insulin delivery devices at competitive prices. Furthermore, to have a strong hold over the market, most vendors are adopting strategies like tie-ups with hospitals and specialty diabetic clinics, online marketing, and home services. These strategies also help vendors to expand their product portfolio. Major players like Novo Nordisk, Sanofi, Eli Lilly, BD, and Medtronic are focusing on enhancing their global and regional presence through M&A and operational expansion. The vendors are also expanding their sales operations in the emerging markets such as India and China to gain high market shares.
Key vendors in the market are
Other prominent vendors in the market are Animas, Beta Bionics, Cellnovo, Copernicus, Dance Biopharm, Debiotech, InsuJet, Insulet, MannKind, Owen Mumford, Roche, SHL Group, SOOIL, Valeritas, West Pharma, and Ypsomed.
According to this market study, the insulin pen segment is anticipated to dominate the market and will account for more than 58% of the total market share by 2020. Insulin pens are the next level of diagnostic devices and are highly user-friendly compared to syringes. Though the cost of insulin pens is higher, they have a good market share in North American countries like the United States and Canada. The governments in APAC countries like Australia and Japan have started introducing these devices under patient reimbursement policies. Furthermore, the R&D cost will increase in the future as there is stiff competition between insulin device manufacturers, which, in turn, would lead to the launch of innovative products in the market.
In this market research, the hospitals are the key end users that greatly influence market growth. Multi-specialty hospitals and hospital groups work under government sponsorship or through private entities, offering a large number of inpatient and outpatient services and generate more revenues. These hospitals work closely with many suppliers, reimbursement authorities, and government organizations in order to procure the delivery of insulin devices.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Market segmentation by product
PART 07: Market segmentation by end-user
PART 08: Geographical segmentation
PART 09: Market drivers
PART 10: Impact of drivers
PART 11: Market challenges
PART 12: Impact of drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Key vendor analysis
PART 16: Appendix
PART 17: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.